These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
52. Clinical pharmacology of the anti-IL-17 receptor antibody brodalumab (KHK4827) in Japanese normal healthy volunteers and Japanese subjects with moderate to severe psoriasis: a randomized, dose-escalation, placebo-controlled study. Osamu N; Hirotaka N; Koji S; Kenji T J Dermatol Sci; 2014 Sep; 75(3):201-4. PubMed ID: 24957501 [No Abstract] [Full Text] [Related]
53. Brodalumab versus ustekinumab in psoriasis. Fioranelli M; Roccia MG; Lotti T Dermatol Ther; 2016 Sep; 29(5):298. PubMed ID: 26627075 [No Abstract] [Full Text] [Related]
54. Eyelid Dermatitis as a Side Effect of Interleukin-17A Inhibitors in Psoriasis. Teraki Y; Takahashi A; Inoue Y; Takamura S Acta Derm Venereol; 2018 Apr; 98(4):456-457. PubMed ID: 29327064 [No Abstract] [Full Text] [Related]
55. Necrotizing pneumonia caused by Panton-Valentine leukocidin-producing methicillin-susceptible Staphylococcus aureus (MSSA). Catena V; Baiocchi M; Lentini P; Badolati L; Baccarin M; Del Monte DD; Rubini A Infez Med; 2012 Sep; 20(3):205-10. PubMed ID: 22992562 [TBL] [Abstract][Full Text] [Related]
56. Hepatitis: a rare, but important, complication of infliximab therapy for psoriasis. Wahie S; Alexandroff A; Reynolds NJ Clin Exp Dermatol; 2006 May; 31(3):460-1. PubMed ID: 16681606 [No Abstract] [Full Text] [Related]
58. Management and outcome of adults with skin and soft tissue infection caused by methicillin-resistant Staphylococcus aureus in a tertiary hospital in central Taiwan. Teh SH; Chi CY; Lin PC; Ho CM; Chou CH; Tsai CT; Wang JH; Ho MW J Microbiol Immunol Infect; 2015 Oct; 48(5):497-503. PubMed ID: 25446039 [TBL] [Abstract][Full Text] [Related]